Effect of angiotensin receptor blockers and angiotensin‐converting enzyme 2 on plasma equilibrium angiotensin peptide concentrations in cats with heart disease

Autor: Kerry A. Loughran, Terry Huh, Éva Larouche-Lebel, Mark A. Oyama
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Heart disease
Heart Diseases
040301 veterinary sciences
Cardiology
Angiotensin-Converting Enzyme Inhibitors
Standard Article
030204 cardiovascular system & hematology
Pharmacology
angiotensin 1‐7
angiotensin II
renin‐angiotensin‐aldosterone‐system
Cat Diseases
0403 veterinary science
Renin-Angiotensin System
03 medical and health sciences
Angiotensin Receptor Antagonists
0302 clinical medicine
Renin–angiotensin system
medicine
Angiotensin-2
Animals
cardiovascular diseases
Prospective Studies
General Veterinary
biology
business.industry
Angiotensin-converting enzyme
04 agricultural and veterinary sciences
medicine.disease
Angiotensin II
Standard Articles
Heart failure
Angiotensin-converting enzyme 2
biology.protein
Cats
SMALL ANIMAL
Angiotensin-Converting Enzyme 2
Telmisartan
business
Peptides
cardiomyopathy
hormones
hormone substitutes
and hormone antagonists
medicine.drug
Zdroj: Journal of Veterinary Internal Medicine
ISSN: 1939-1676
0891-6640
Popis: Background The pathophysiology of heart failure involves maladaptive angiotensin peptides (APs) and enzymes, including angiotensin 2 (AT2) and angiotensin converting enzyme (ACE), as well as recently described alternative components, such as angiotensin 1-7 (Ang1-7) and angiotensin converting enzyme 2 (ACE2). The relative effects of different neurohormonal-targeting drugs on balance of APs in dogs with heart disease are unknown. Hypothesis/objectives Plasma AP concentrations differ in dogs receiving angiotensin converting enzyme inhibitors (ACEIs) vs angiotensin receptor blockers (ARBs) and recombinant human ACE2 (rhACE2) will further increase these differences. Animals Eight dogs with degenerative mitral valve disease (DMVD). Methods Prospective open-label trial. Equilibrium concentrations of APs from plasma during PO ACEI treatment and then after 14 days of PO ARB treatment using telmisartan were measured using liquid chromatography-tandem mass spectroscopy before and after in vitro incubation with rhACE2. Results Concentration of Ang1-7 was increased during ARB treatment (Ang1-7: 443 pg/mL; 95% confidence interval [CI] = 247-794 pg/mL) vs ACEI (Ang1-7: 182 pg/mL; 95% CI = 66.2-503 pg/mL; P = .01). Incubation with rhACE2 decreased traditional APs while increasing beneficial alternative APs, and Ang1-7 was significantly higher in the ARB + rhACE2 (880 pg/mL; 95% CI = 560-1383 pg/mL) vs ACEI + rhACE2 (455 pg/mL; 95% CI = 188-1104 pg/mL; P = .03) group. The most favorable theoretical AP profile was achieved in the ARB + rhACE2 group. Conclusions and clinical importance The AP profile during telmisartan treatment is associated with higher plasma Ang1-7 as compared with during ACEI. This favorable shift is potentiated in vitro by combination of ARB + rhACE2. These data support potential AP-targeting strategies and drugs in dogs with DMVD.
Databáze: OpenAIRE
Externí odkaz: